Relacorilant (Lifyorli)

Key facts

• Lifyorli is used with nab-paclitaxel, not as a stand-alone cancer treatment in the approved indication.
• The approved population must meet disease-type and prior-treatment requirements in the current label.
• The FDA approval was based on the randomized ROSELLA trial.
• The prescribing information includes important precautions, interactions, and blood-count monitoring.

What the 2026 FDA approval covers

The approval covers adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who received one to three prior systemic treatment regimens, with at least one including bevacizumab.

The approval does not mean relacorilant is appropriate for every ovarian cancer or for use outside the labeled combination.

Safety and interaction context

The FDA patient information warns that Lifyorli with nab-paclitaxel can cause low white blood cell counts, fever, and serious infections. The full label contains additional adverse reactions and drug-interaction instructions.

Patients should use the current label and oncology team for individualized monitoring and medication-interaction review.

Primary sources

• FDA: relacorilant with nab-paclitaxel approval — FDA approval notification dated March 25, 2026.
• FDA: Lifyorli prescribing information — FDA label with the approved population, combination regimen, safety information, and interactions.